Molecular basis of sulindac competition with specific markers for the major binding sites on human serum albumin.

Article Details

Citation

Copy to clipboard

Russeva VN, Zhivkova ZD

Molecular basis of sulindac competition with specific markers for the major binding sites on human serum albumin.

Arzneimittelforschung. 2003;53(3):174-81.

PubMed ID

12705172 [ View in PubMed

]

Abstract

This study deals with the competitive interactions of sulindac (CAS 38194-50-2) with specific markers for the major binding areas on human serum albumin (HSA): phenylbutazone (CAS 50-33-9) and warfarin (CAS 129-06-6) for Site I, and diazepam (CAS 439-14-5) for Site II. The method used is high-performance liquid affinity chromatography with HSA-immobilized stationary phase. The affinity constants during the cobinding are determined, and the major thermodynamic parameters are calculated. Based on that the nature of the intermolecular interactions involved in the binding process is hypothesized. The cobinding of sulindac and phenylbutazone is simple competitive and is dominated by hydrogen bonds. The binding affinity of sulindac is significantly decreased by R-warfarin (anticooperative binding), and conformational changes resulting in alteration of the binding mechanisms (electrostatic as well as hydrophobic interactions) are supposed. S-Warfarin hardly affects the binding affinity of sulindac. Sulindac competes with diazepam for two types of binding site: high affinity Site II where the cobinding seems to be dominated by hydrophobic bonding, and low affinity Site I, the latter affinity being significantly decreased (anticooperative binding). These results contribute to a better understanding of the molecular mechanisms of the binding of the investigated drugs with HSA.

DrugBank Data that Cites this Article

Drug Carriers

Drug	Carrier	Kind	Organism	Pharmacological Action	Actions
Sulindac	Serum albumin	Protein	Humans	Unknown	Not Available	Details